C16orf91

Across TCGA pan-cancer cohorts, C16orf91 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C16orf91 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C16orf91 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C16orf91 expression acts as an unfavorable survival marker.

STAD, BRCA, and BLCA are the cancer types where C16orf91 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
BRCA	OS	Median	All	0.313	0.924	<.001	30	view →
BLCA	DFS	Median	All	0.187	0.627	.006	15	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C16orf91–STAD (OS)

Open the STAD breakdown →